Evidence map›Paper›PMID 36124718›Full record

ArticleClinical cardiology2022

Predictive value of HMGB1 for atrial fibrillation recurrence after cryoballoon ablation in paroxysmal atrial fibrillation patients.

Xinxin Li, Cuiting Zhao, Meng Li, Hongxiao Yu, Xiping Liu, Qing Zhu, Xiaokun Song, Yonghuai Wang, Bo Yu, Chunyan Ma

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xinxin LiDepartment of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Cuiting ZhaoDepartment of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Meng LiDepartment of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Hongxiao YuDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Xiping LiuDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Qing ZhuDepartment of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Xiaokun SongDepartment of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Yonghuai WangDepartment of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Bo YuDepartment of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Chunyan MaDepartment of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, Liaoning, China.ORCID http://orcid.org/0000-0002-3327-736X
First Hospital of China Medical University · CN

Funding

National Natural Science Foundation of China 81871373
6 · The paper itself

Abstract

backgroundCryoballoon ablation (CBA) is recommended for patients with symptomatic drug refractory paroxysmal atrial fibrillation (pAF). However, substantial atrial fibrillation (AF) recurrence is common during follow-up. Searching for a potential biomarker representing both myocardial injury and inflammation to identify patients at high risk of AF recurrence after CBA is very meaningful for postoperative management of AF patients. HYPOTHESIS: To evaluate the clinical efficacy of high-mobility group box 1 (HMGB1) protein released from the left atrium to predict AF recurrence in pAF patients after CBA at 1-year follow-up.

methodsWe included 72 pAF patients who underwent CBA. To determine the expression levels of HMGB1, left atrial blood samples were collected from the patients before CBA and after the procedure through the transseptal sheath. Patients were followed up for AF recurrence for 1 year.

resultsA total of 19 patients of the 72 experienced AF recurrence. The level of postoperative HMGB1 (HMGB1post) was higher in the AF recurrence group than in the AF non recurrence group (p = .03). However, no differences were noted in the levels of other biomarkers such as preoperative high-sensitivity C-reactive protein (hs-CRP), postoperativehs-CRP, and preoperative HMGB1 between the two groups. Multiple logistic regression analysis revealed that a higher level of serum HMGB1post was associated with AF recurrence (odds ratio: 5.29 [1.17-23.92], p = .04). Receiver operating characteristic analysis revealed that HMGB1post had a moderate predictive power for AF recurrence (area under the curve: 0.68; sensitivity: 72%; and specificity: 68%). The 1-year AF-free survival was significantly lower in patients with a high HMGB1post level than in those with a low HMGB1post level (hazard ratio: 3.81 [1.49-9.75], p = .005).

conclusionIn pAF patients who under went CBA, the level of HMGB1 after CBA was associated with AF recurrence and demonstrated a moderate predictive power. Thus, we offer a potential biomarker to identify pAF patients at high risk of AF recurrence.

Indexed as

Atrial FibrillationCatheter AblationCryosurgeryHMGB1 ProteinBiomarkersHumansTreatment OutcomeBiomarkersHMGB1 Proteinatrial fibrillation recurrencecryoballoon ablationHMGB1paroxysmal atrial fibrillation

Identifiers

PMID36124718
PMCPMC9748753
OpenAlexW4297855502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.